New shot could simplify breast cancer treatment before surgery

NCT ID NCT07166185

Recruiting now Disease control Sponsor: Blida 1 University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a drug called Phesgo, given as a shot under the skin, for women with early-stage HER2-positive breast cancer before they have surgery. About 70 women in Algeria will receive Phesgo along with standard chemotherapy for about 18 weeks. The main goal is to see how many women have no cancer left in the breast or lymph nodes after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Phesgo (a combination of trastuzumab and pertuzumab given as a shot under the skin)
What this could lead to: If this works, it could show that a simpler, faster shot can replace longer IV treatments for HER2-positive breast cancer before surgery, making care easier for patients and hospitals.
What could go wrong: This is a small, early-phase study with only 70 women in Algeria. It may not prove the treatment works better than standard care, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates